title: Down-regulated miR-22 as predictive biomarkers for prognosis of epithelial ovarian cancer.
abstract: BACKGROUND
  Recent studies have demonstrated that microRNA-22 (miR-22) was deregulated in many types of cancers and was involved in various cellular processes related to carcinogenesis. However, the clinical significance and prognostic value of miR-22 in epithelial ovarian cancer (EOC) haven't been investigated.
  
  
  METHODS
  109 pairs of fresh EOC tissue and matched adjacent normal tissue specimens were collected between May 2007 and March 2013. Real-time quantitative RT-PCR assay was performed to evaluate the expression levels of miR-22. The chi-square test was used to assess miR-22 expression with respect to clinicopathological parameters. The survival curves of the patients were determined using the Kaplan-Meier method and Cox regression, and the log-rank test was used for statistical evaluations.
  
  
  RESULTS
  miR-22 expression in EOC tissues was significantly lower than that in matched normal adjacent tissues (mean ± SD: 1.944 ± 1.026 vs. 4.981 ± 1.507, P<0.0001). Low miR-22 expression level was correlated with FIGO stage (P=0.006), tumor grade (P=0.03), and lymph node metastases (P=0.01). Kaplan-Meier analysis with the log-rank test indicated that low miR-22 expression had a significant impact on overall survival (44.4% vs. 64.5%; P=0.005) and progression-free survival (23.5% vs. 52.6%; P=0.004).
  
  
  CONCLUSIONS
  Our data demonstrated that the expression of miR-22 was downregulated in EOC, and associated with overall survival as well as progression-free survival, suggesting that miR-22 could serve as an efficient prognostic factor for EOC patients.
  The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_178.
authors.forename: Wei-na
authors.initials: WN
authors.lastname: Wan
authors.forename: Yu-qin
authors.initials: YQ
authors.lastname: Zhang
authors.forename: Xue-mei
authors.initials: XM
authors.lastname: Wang
authors.forename: Yan-jun
authors.initials: YJ
authors.lastname: Liu
authors.forename: Yi-xia
authors.initials: YX
authors.lastname: Zhang
authors.forename: Yan-hong
authors.initials: YH
authors.lastname: Que
authors.forename: Wen-jing
authors.initials: WJ
authors.lastname: Zhao
authors.forename: Ping
authors.initials: P
authors.lastname: Li
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D016009:Chi-Square Distribution; D015536:Down-Regulation / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006801:Humans; D053208:Kaplan-Meier Estimate; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism; D010053:Ovary / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D014408:Biomarkers, Tumor; C548375:MIRN22 microRNA, human; D035683:MicroRNAs